Articles by Johannes G. Khinast - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Johannes G. Khinast

Johannes G. Khinast


Johannes G. Khinast is a professor at the Graz University in Austria and Head of the Institute of Process and Particle Engineering Scientific Director Research Center Pharmaceutical Engineering (RCPE).

Articles
Comparing Manufacturing Process Options
August 2, 2014

A techno-economic profiling method supports pharmaceutical process development by helping identify the best manufacturing approach.

Peer Reviewed: Numerical Simulation of Tablet Coating
September 2, 2012

The authors investigate the tablet-coating process using a combination of different simulation techniques.

Printable Medicines: A Microdosing Device For Producing Personalized Medicines
January 7, 2011

The authors describe a new method for the production of personalised medicines utilising ultra-precise microdrop printing technology.

Effect of Droplet-Wake Phenomena on Mixing-Sensitive Pharmaceutical Reactions
November 2, 2006

Understanding the impact of reactive mass transfer and local flow in multiphase systems is crucial for maximizing reaction selectivity and minimizing the formation of byproducts. The authors study the influence of mixing on fast liquid–liquid reactions. The iodination of L-tyrosine was used to demonstrate the relationship of droplet size and shape on reaction selectivity and to verify computational predictions. By understanding that droplet dynamics affect the yield and selectivity of fast reactions, the formation of byproducts can be minimized by optimizing operating parameters.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here